About

Executive Chairman of the board since August 2020. Former President and CEO of Gilead Sciences (2016-2019) after 29 years at Gilead. Serves on the boards of Pacific Biosciences of California and Kailera Therapeutics.

Roles

4D Molecular Therapeutics, Inc.
Director and Executive Chairman · Current role
2020–present

Director Compensation

FY 2025
Fees earned or paid in cash
$150,000
Option awards
$105,000
Total
$255,000

Also at 4D Molecular Therapeutics, Inc.

Colleague
David Kirn, M.D.
Co-Founder, President, Chief Executive Officer and Director
Colleague
Jacob Chacko, M.D., MBA
Director
Colleague
Susannah Gray, MBA
Director

Related

Company
4D Molecular Therapeutics, Inc.
Company hub

See how VectorShift works for your firm

Request Demo